INTERVIEW: Bausch & Lomb eyes market listing as acquisition offers roll in
This article was originally published in Scrip
Executive Summary
The 160-year-old eye drug, surgery and consumer product specialist Bausch & Lomb checked a box on the to-do list for its return to the public markets with a stop at the 31st Annual JP Morgan Healthcare Conference in San Francisco, during a period when the company also is getting offers from Big Pharma suitors.
You may also be interested in...
Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma
Allergan is building a diverse ophthalmology portfolio with a pipeline of drugs, devices and procedures that could bolster the company’s eye care revenue beyond Restasis and glaucoma medicines.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.